Search Result

Results for "

viral protein synthesis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (11) Autophagy (3) Bacterial (4) CMV (3) Cytochrome P450 (1) EBV (1) Endogenous Metabolite (2) Enterovirus (3) Fatty Acid Synthase (FASN) (2) Flavivirus (1) HCV (6) HSV (4) Influenza Virus (1) Isotope-Labeled Compounds (1) Nucleoside Antimetabolite/Analog (1) Orthopoxvirus (2) Reference Standards (3) RSV (3) SARS-CoV (2) TNF Receptor (1) VSV (1) VZV (1)
By Research Areas:	Cancer (4) Infection (24) Inflammation/Immunology (1)
Oligonucleotides:	Nucleoside Analogs (1) Uridine (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: DNA/RNA Synthesis

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-E70529

Ribonucleoside vanadyl complexes	DNA/RNA Synthesis Bacterial	Infection
Ribonucleoside vanadyl complexes are a class of potent RNase and Taq polymerase inhibitors. Ribonucleoside vanadyl complexes protect RNA during RNA isolation by inhibiting ribonucleases, and also reduce the viability of bacteria and eukaryotic cells by interfering with ribosomal subunit assembly. Ribonucleoside vanadyl complexes block PCR and reverse transcription reactions templated by viral nucleic acids and enhance the effects of antibiotics against Staphylococcus aureus, but do not directly inhibit protein synthesis. Ribonucleoside vanadyl complexes can be effectively removed by phenol-chloroform extraction, thus enabling subsequent PCR analysis. Ribonucleoside vanadyl complexes can be applied in research related to chronic hepatitis C (HCV) and Staphylococcus aureus infection .

HY-128744

Phosphonoacetic acid 2 Publications Verification	Endogenous Metabolite Orthopoxvirus HSV DNA/RNA Synthesis	Infection
Phosphonoacetic acid is an endogenous metabolite and antiviral agent. Phosphonoacetic acid is active against orthopoxviruses and herpes viruses. Phosphonoacetic acid can inhibit HSV DNA synthesis and virus-specific DNA polymerase activity, and affect the synthesis of late viral proteins .

HY-N0093

Ancitabine hydrochloride 1 Publications Verification Cyclocytidine hydrochloride; Cyclo-CMP hydrochloride; Cyclo-C	Autophagy CMV DNA/RNA Synthesis	Infection Cancer
Ancitabine hydrochloride is a cytarabine derivative that inhibits viral replication. Ancitabine hydrochloride blocks vaccinia virus DNA replication, the progression of viral protein synthesis from early to late stages, and one-step growth of vaccinia virus. Ancitabine hydrochloride is applicable to research related to vaccinia virus infection, leukemia, human cytomegalovirus infection and colorectal cancer .

HY-N2036

Mosloflavone 1 Publications Verification	TNF Receptor Enterovirus Bacterial	Infection
Mosloflavone is a flavonoid isolated from Scutellaria baicalensis Georgi with ?anti-EV71 activity. Mosloflavone? inhibits VP2 virus replication and protein expression during the initial stage of virus infection and inhibits viral VP2 capsid protein synthesis. Mosloflavone is a promising biocide and inhibits P. aeruginosa virulence and biofilm formation.

HY-172760

CIM-834	SARS-CoV	Infection
CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19 .

HY-110354

UCM05 2 Publications Verification G28UCM	Fatty Acid Synthase (FASN) Bacterial	Infection
UCM05 (G28UCM) is a fatty acid synthase (FASN) and *filamentous temperature-sensitive protein* Z (Ftsz*) inhibitor. UCM05 inhibits fatty acid synthesis, viral* replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections^[1][2][3].

HY-124806

TTP-8307 2 Publications Verification	Enterovirus DNA/RNA Synthesis HCV	Infection
TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC₅₀=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP) .

HY-10118

Filibuvir 4 Publications Verification	HCV DNA/RNA Synthesis	Infection
Filibuvir is an orally active, selective non-nucleoside inhibitor of the *HCV nonstructural 5B protein* (NS5B) RNA-dependent RNA polymerase (RdRp)*. Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC₅₀s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis* and potently decreases viral RNA accumulation .

HY-148170

L-I-OddU	EBV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Infection
L-I-OddU, a L-5'-halo- dioxolane nucleoside analogue, is a potent and selective anti-Epstein-Barr virus (EBV) agent with an EC₅₀ value of 0.03μM. L-I-OddU has low cytotoxicity with a CC₅₀ value of 1000 nM. L-I-OddU has antiviral activity by suppressing replicative EBV DNA and viral protein synthesis .

HY-W555382

Pseudane IX 2-Nonylquinolin-4(1H)-one	HCV	Infection
Pseudane IX, a compound isolated from the leaves of Ruta angustifolia, has strong anti-HCV activity with an IC₅₀ value of 1.4 μg/mL. Pseudane IX reduces HCV RNA replication and viral protein synthesis levels .

HY-163529

HN0037	HSV Cytochrome P450	Infection
HN0037 is a selective, orally active Helicase-primase inhibitor. HN0037 is mainly metabolized by CYP3A4. HN0037 inhibits HSV replication by targeting the viral helicase-primase complex, which consists of three proteins encoded by UL5 (helicase), UL52 (primase), and UL8 (scaffold protein that promotes primer synthesis) .

HY-111233

Disoxaril WIN-51711	Enterovirus	Infection
Disoxaril (WIN-51711) is an antivirus agent with activity against poliovirus types 1 and 2. Disoxaril inserts into the hydrophobic interior of virus capsid protein VP1 to stabilize virion conformation, inhibits poliovirus uncoating, and prevents viral RNA release and synthesis. Disoxaril can be used for the research of poliovirus infection .

HY-115574

RSV L-protein-IN-1	RSV	Infection
RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC₅₀=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC₅₀=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .

HY-122668

K22	SARS-CoV DNA/RNA Synthesis	Infection
K22 is an anti-Coronaviral compound. K22 reduces double-stranded RNA. K22 displays antiviral activity beyond the Coronavirinae subfamily, namely against nidoviruses of the Torovirinae subfamily (EToV and WBV) and members of the Arteriviridae family (PRRSV, EAV). K22 displays antiviral activity against HCoV-229E .

HY-173189B

2-5A TEA 2′,5′-ApApA TEA; 2′,5′-trioligoadenylate TEA; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine TEA	RSV DNA/RNA Synthesis	Infection Inflammation/Immunology Cancer
2-5A (2′,5′-ApApA; 2′,5′-trioligoadenylate; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine) TEA is a 5'-triphosphorylated (2',5') oligoadenylate. 2-5A TEA is an immunotransmitter that fuels RNase L immunity. 2-5A TEA degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its endoribonuclease activity. 2-5A TEA can be used in RSV and cancer research .

HY-N0093A

Ancitabine Cyclocytidine; Cyclo-CMP	DNA/RNA Synthesis CMV Autophagy	Cancer
Ancitabine is a cytarabine derivative that inhibits viral replication. Ancitabine blocks vaccinia virus DNA replication, the progression of viral protein synthesis from early to late stages, and one-step growth of vaccinia virus. Ancitabine is applicable to research related to vaccinia virus infection, leukemia, human cytomegalovirus infection and colorectal cancer .

HY-107009

CTC 96	VZV HSV VSV	Infection
CTC 96 is an antiviral agent, showing inhibitory effects particularly on herpes viruses and adenoviruses. CTC 96 directly blocks the fusion process between the viral envelope and the cell membrane, preventing the entry of viral nucleic acids and proteins into the cells. CTC 96 can completely block the penetration and intercellular transmission of HSV-1, preventing the synthesis of viral proteins and mRNA. CTC 96 exhibits significant anti-adenovirus activity in rabbit eye models. CTC 96 is also effective against varicella-zoster virus (VZV) and vesicular stomatitis virus (VSV). CTC 96 can be used for broad-spectrum antiviral research .

HY-N0093R

Ancitabine hydrochloride (Standard) Cyclocytidine hydrochloride (Standard); Cyclo-CMP hydrochloride (Standard); Cyclo-C (Standard)	Reference Standards Autophagy CMV DNA/RNA Synthesis	Cancer
Ancitabine hydrochloride (Standard) is the analytical standard of Ancitabine hydrochloride. This product is intended for research and analytical applications. Ancitabine hydrochloride is a cytarabine derivative that inhibits viral replication. Ancitabine hydrochloride blocks vaccinia virus DNA replication, the progression of viral protein synthesis from early to late stages, and one-step growth of vaccinia virus. Ancitabine hydrochloride is applicable to research related to vaccinia virus infection, leukemia, human cytomegalovirus infection and colorectal cancer .

HY-128744R

Phosphonoacetic acid (Standard)	Reference Standards Endogenous Metabolite Orthopoxvirus HSV DNA/RNA Synthesis	Infection
Phosphonoacetic acid (Standard) is the analytical standard of Phosphonoacetic acid (HY-128744). This product is intended for research and analytical applications. Phosphonoacetic acid is an endogenous metabolite and antiviral agent. Phosphonoacetic acid is active against orthopoxviruses and herpes viruses. Phosphonoacetic acid can inhibit HSV DNA synthesis and virus-specific DNA polymerase activity, and affect the synthesis of late viral proteins .

HY-111026

PPQ-581	Influenza Virus	Infection
PPQ-581 is an anti-influenza agent with an EC₅₀ of 1 μM for preventing virus-induced cytopathic effects. PPQ-581 inhibits viral protein synthesis. PPQ-581 blocks the RNP nuclear export and cytoplasmic RNP aggregation .

HY-154968

RSV L-protein-IN-5	RSV	Infection
RSV L-protein-IN-5 (compound E) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC₅₀=0.1 μM). RSV L-protein-IN-5 inhibits Polymerase (IC₅₀=0.66 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-5 shows moderate cytotoxicity (CC50=10.7 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .

HY-W555382S

Pseudane IX-d4 2-Nonylquinolin-4(1H)-one-d₄	Isotope-Labeled Compounds HCV	Infection
Pseudane IX-d₄ (2-Nonylquinolin-4(1H)-one-d₄) is deuterium labeled Pseudane IX. Pseudane IX, a compound isolated from the leaves of Ruta angustifolia, has strong anti-HCV activity with an IC₅₀ value of 1.4 μg/mL. Pseudane IX reduces HCV RNA replication and viral protein synthesis levels .

HY-171587

3′-Deoxy CTP	HCV	Infection
3′-Deoxy CTP is a nucleotide analogue and a mandatory chain terminator. 3′-Deoxy CTP can cause chain termination by lacking the 3′-hydroxyl group, inhibiting the RNA synthesis activity of HCV nonstructural protein (NS5B) polymerase and blocking viral replication. 3′-Deoxy CTP can be used to study the chain termination mechanism of HCV polymerase and the development of antiviral drugs .

HY-171587A

3′-Deoxy CTP trisodium	HCV	Infection
3′-Deoxy CTP trisodium is the sodium salt form of 3′-Deoxy CTP (HY-171587). 3′-Deoxy CTP trisodium is a nucleotide analogue and a mandatory chain terminator. 3′-Deoxy CTP trisodium can cause chain termination by lacking the 3′-hydroxyl group, inhibiting the RNA synthesis activity of HCV nonstructural protein (NS5B) polymerase and blocking viral replication. 3′-Deoxy CTP trisodium can be used to study the chain termination mechanism of HCV polymerase and the development of antiviral drugs .

HY-110354R

UCM05 (Standard) G28UCM (Standard)	Reference Standards Fatty Acid Synthase (FASN) Bacterial	Infection
UCM05 (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. UCM05 (G28UCM) is a fatty acid synthase (FASN) and *filamentous temperature-sensitive protein* Z (Ftsz*) inhibitor. UCM05 inhibits fatty acid synthesis, viral* replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections ^[1][2][3].

HY-183314

ZIKV-IN-9	Flavivirus	Infection
ZIKV-IN-9 is a ZIKV inhibitor that blocks the early binding of viral particles to the cell surface. ZIKV-IN-9 inhibits ZIKV in various cell models. ZIKV-IN-9 is applicable to research related to Zika virus infection .

Cat. No.	상품명

HY-L940

Antiviral Lead-like compound library	5,813 compounds
Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs. These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance. This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Antiviral Lead-like compound library

5,813 compounds

Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs.

These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance.

This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Cat. No.	상품명	Category	Target	Chemical Structure